Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Auditor change
Inhibitor Therapeutics, Inc. (HPPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/23/2023 SC 13D Black Robe Capital LLC reports a 15.7% stake in INHIBITOR THERAPUTICS, INC.
05/23/2023 SC 13G TPB 2012 LLC reports a 16.4% stake in Inhibitor Therapeutics, Inc.
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/31/2023 10-K Annual Report for the period ended December 31, 2022
12/19/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Notice of Pendency of Derivative and Class Actions, Proposed Settlement and Settlement Hearing",
"Notice of Pendency of Derivative and Class Actions, Proposed Settlement and Settlement Hearing"
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/03/2022 8-K Quarterly results
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
03/30/2022 10-K Annual Report for the period ended December 31, 2021
01/18/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Letter Agreement to Amend Term Debt Facility, between the Company and Mayne Pharma"
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
08/13/2021 10-Q Quarterly Report for the period ended June 30, 2021
05/14/2021 10-Q Quarterly Report for the period ended March 31, 2021
03/26/2021 10-K Annual Report for the period ended December 31, 2020
01/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/17/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lender: Mayne Pharma Ventures Pty Ltd or its nominated affiliate Borrower: Inhibitor Therapeutics, Inc. Structure: Term Debt Facility Line Amount: USD231,000 Availability: USD81,000 in the first annual quarter of the term starting 14 December 2020 and USD75,000 in each of the subsequent second and third annual quarters, unless Mayne Pharma, acting in its sole and absolute discretion, gives notice to INTI at least 30 days before the start of a quarter that it is discontinuing funding and that INTI will not be able to draw down additional funds. 1 Purpose: General working capital and corporate purposes as the Board of INTI considers appropriate to meet its legal and regulatory requirements, payment of the outstanding accounts payable and the transaction costs listed on Schedule 1 hereto, and..."
11/16/2020 10-Q Quarterly Report for the period ended September 30, 2020
09/23/2020 8-K Quarterly results
08/12/2020 10-Q Quarterly Report for the period ended June 30, 2020
06/30/2020 8-K Quarterly results
06/08/2020 8-K Other Events
05/06/2020 8-K Quarterly results
05/01/2020 10-Q Quarterly Report for the period ended March 31, 2020
04/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/30/2020 10-K Annual Report for the period ended December 31, 2019
02/10/2020 5 Watson W. Mark (Director) has filed a Form 5 on Inhibitor Therapeutics, Inc.
01/03/2020 8-K Quarterly results
12/05/2019 DEF 14C Form DEF 14C - Other definitive information statements:
11/07/2019 10-Q Quarterly Report for the period ended September 30, 2019
10/31/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy